[Adjuvant concurrent chemoradiotherapy for resected locally advanced lung cancer outpatients]

Recently, adjuvant chemoradiotherapy showed possible survival advantage in the western prospective studies. A feasibility study was conducted. Adjuvant concurrent chemoradiotherapy with carboplatin (CBDCA) + paclitaxel (PTX) was performed to 4 outpatients with resected locally advanced lung cancer. A total of 60 Gy was given during about 7 weeks, and concurrent CBDCA 2 mg/AUC + PTX 45 mg/m2 was administered weekly. Grade 2 neutropenia was seen in 2 patients, grade 2 esophagitis was seen in 1, and grade 2 peripheral neuritis was in 1. Grade 3 or more toxicity was never seen. One patient had to be hospitalized because of esophagitis, but other 3 patients had completed all course of the therapy as outpatients. Adjuvant concurrent chemoradiotherapy with CBDCA + PTX was thought to be feasible to the resected locally advanced lung cancer patients. Prospective study will be conducted to examine the efficacy of this treatment.